We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
-17.32%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$163M
AUM Growth
-$123M
Cap. Flow
-$51.4M
Cap. Flow %
-31.48%
Top 10 Hldgs %
100%
Holding
11
New
–
Increased
1
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
BCAX
Bicara Therapeutics
BCAX
+$3.23M

Top Sells

Rank Stock Value
1
UPB
Upstream Bio Inc
UPB
+$36M
2
ALMS
Alumis Inc
ALMS
+$10.3M
3
KMTS
Kestra Medical Technologies
KMTS
+$8.28M

Sector Composition

Rank Sector Weight
1 Healthcare 100%

No holdings matched the selected filter criteria.

Similar funds

PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return
GP
Gridiron Partners Wexford, Pennsylvania $164M AUM 3.31% 1-Year Est. Return
PWAM
Papamarkou Wellner Asset Management New York $164M AUM 25.23% 1-Year Est. Return
ACM
Alamar Capital Management Santa Barbara, California $164M AUM 19.77% 1-Year Est. Return

Omega Fund Management's Q1 2026 Portfolio in Review

As of Q1 2026, Omega Fund Management held 11 positions worth $163M, down 43% from $287M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Omega Fund Management withdrew a net $51.4M in Q1 2026, closing 1 position and reducing 2 holdings. Its most notable exit was Upstream Bio Inc, an estimated $36M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Omega Fund Management added an estimated $3.23M to Bicara Therapeutics.

  • Omega Fund Management added most to Bicara Therapeutics in Q1 2026, an estimated $3.23M increase.
  • Omega Fund Management's biggest Q1 2026 reduction was Alumis Inc, cutting an estimated $10.3M.
  • Omega Fund Management fully exited Upstream Bio Inc in Q1 2026, selling an estimated $36M.
  • Omega Fund Management's ten largest holdings make up 100% of its $163M portfolio in Q1 2026.
  • Omega Fund Management opened 0 new positions and closed 1 in Q1 2026.
  • Omega Fund Management's portfolio value fell 43% quarter-over-quarter to $163M.

Based on Omega Fund Management's 13F filing for Q1 2026, filed 15 May 2026.